JP2015524472A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524472A5 JP2015524472A5 JP2015526606A JP2015526606A JP2015524472A5 JP 2015524472 A5 JP2015524472 A5 JP 2015524472A5 JP 2015526606 A JP2015526606 A JP 2015526606A JP 2015526606 A JP2015526606 A JP 2015526606A JP 2015524472 A5 JP2015524472 A5 JP 2015524472A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- alkyl
- deuterium
- inhibitor
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 10
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 8
- 229910052805 deuterium Inorganic materials 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 230000002062 proliferating effect Effects 0.000 claims 7
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims 6
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims 6
- 229940121647 egfr inhibitor Drugs 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 229960005395 cetuximab Drugs 0.000 claims 3
- -1 cyano, aminocarbonyl Chemical group 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 239000012828 PI3K inhibitor Substances 0.000 claims 2
- 229940124607 PI3Kα inhibitor Drugs 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 2
- OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680473P | 2012-08-07 | 2012-08-07 | |
| US61/680,473 | 2012-08-07 | ||
| PCT/US2013/053619 WO2014025688A1 (en) | 2012-08-07 | 2013-08-05 | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018022248A Division JP6595024B2 (ja) | 2012-08-07 | 2018-02-09 | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524472A JP2015524472A (ja) | 2015-08-24 |
| JP2015524472A5 true JP2015524472A5 (https=) | 2016-09-15 |
| JP6342396B2 JP6342396B2 (ja) | 2018-06-13 |
Family
ID=48980368
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526606A Active JP6342396B2 (ja) | 2012-08-07 | 2013-08-05 | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
| JP2018022248A Active JP6595024B2 (ja) | 2012-08-07 | 2018-02-09 | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
| JP2019174353A Active JP6974669B2 (ja) | 2012-08-07 | 2019-09-25 | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018022248A Active JP6595024B2 (ja) | 2012-08-07 | 2018-02-09 | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
| JP2019174353A Active JP6974669B2 (ja) | 2012-08-07 | 2019-09-25 | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
Country Status (39)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6342396B2 (ja) * | 2012-08-07 | 2018-06-13 | ノバルティス アーゲー | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
| MA38522A1 (fr) | 2013-03-21 | 2017-10-31 | Novartis Ag | Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur. |
| WO2015145388A2 (en) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
| EP3392348A3 (en) * | 2014-06-16 | 2018-11-21 | Worldwide Innovative Network | Method for selecting personalized tri-therapy for cancer treatment |
| WO2016193955A1 (en) * | 2015-06-04 | 2016-12-08 | Giorgio Stassi | Combinations of kinase inhibitors for treating colorectal cancer |
| US20180256557A1 (en) * | 2015-08-28 | 2018-09-13 | Giordano Caponigro | Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer |
| EP3355886A1 (en) * | 2015-08-28 | 2018-08-08 | Novartis AG | Pharmaceutical combination comprising the pi3k inhibitor alpelisib and the b-raf inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| FI3463345T3 (fi) * | 2016-06-03 | 2023-01-31 | Farmaseuttisia yhdistelmiä | |
| AU2017329090B9 (en) * | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| CA3057969A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| KR20200036880A (ko) * | 2017-08-03 | 2020-04-07 | 노파르티스 아게 | 3세대 EGFR 타이로신 키나아제 억제제 및 Raf 억제제의 치료적 조합물 |
| MX2021003904A (es) | 2018-10-05 | 2021-10-26 | Annapurna Bio Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj. |
| TWI849043B (zh) * | 2019-01-25 | 2024-07-21 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
| WO2020164997A1 (en) * | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
| EP3969449B1 (en) | 2019-05-13 | 2025-02-12 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| WO2023145530A1 (ja) * | 2022-01-27 | 2023-08-03 | 国立大学法人東北大学 | 癌治療剤 |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| EP4593831A1 (en) * | 2022-09-26 | 2025-08-06 | Mapkure, LLC | Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer |
| WO2025003956A1 (en) | 2023-06-30 | 2025-01-02 | Pfizer Inc. | High drug loading formulations of encorafenib |
| WO2025262686A1 (en) * | 2024-06-20 | 2025-12-26 | Ilan Paz | Devices, systems and methods for optimized, personalized administration of oral dosage forms |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| MY150697A (en) | 2007-04-10 | 2014-02-28 | Exelixis Inc | Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| US20120214828A1 (en) | 2009-08-24 | 2012-08-23 | Georgia Hatzivassiliou | Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels |
| AR077975A1 (es) * | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| EP2488184A4 (en) | 2009-10-12 | 2013-04-24 | Glaxosmithkline Llc | COMBINATION |
| US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| MX360157B (es) * | 2010-11-08 | 2018-10-24 | Novartis Ag | Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades dependientes de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr. |
| US20140275174A1 (en) | 2011-11-10 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES |
| RU2622015C2 (ru) * | 2011-11-11 | 2017-06-08 | Новартис Аг | Способ лечения пролиферативного заболевания |
| JP6342396B2 (ja) * | 2012-08-07 | 2018-06-13 | ノバルティス アーゲー | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 |
-
2013
- 2013-08-05 JP JP2015526606A patent/JP6342396B2/ja active Active
- 2013-08-05 HR HRP20190537TT patent/HRP20190537T1/hr unknown
- 2013-08-05 NZ NZ703940A patent/NZ703940A/en unknown
- 2013-08-05 HK HK15110834.2A patent/HK1211831A1/xx unknown
- 2013-08-05 DK DK13748243.6T patent/DK2882440T3/da active
- 2013-08-05 HU HUE13748243A patent/HUE042877T2/hu unknown
- 2013-08-05 AR ARP130102776A patent/AR092045A1/es not_active Application Discontinuation
- 2013-08-05 UA UAA201500424A patent/UA115786C2/uk unknown
- 2013-08-05 PT PT13748243T patent/PT2882440T/pt unknown
- 2013-08-05 MX MX2015001732A patent/MX359403B/es active IP Right Grant
- 2013-08-05 US US14/419,256 patent/US9474754B2/en active Active
- 2013-08-05 CN CN201380042229.5A patent/CN104519887B/zh active Active
- 2013-08-05 WO PCT/US2013/053619 patent/WO2014025688A1/en not_active Ceased
- 2013-08-05 PE PE2015000130A patent/PE20150673A1/es not_active Application Discontinuation
- 2013-08-05 AU AU2013299841A patent/AU2013299841B8/en active Active
- 2013-08-05 PE PE2019001539A patent/PE20191655A1/es unknown
- 2013-08-05 CA CA2879548A patent/CA2879548C/en active Active
- 2013-08-05 EP EP13748243.6A patent/EP2882440B1/en active Active
- 2013-08-05 SG SG11201500321YA patent/SG11201500321YA/en unknown
- 2013-08-05 IN IN450DEN2015 patent/IN2015DN00450A/en unknown
- 2013-08-05 MY MYPI2015000102A patent/MY176031A/en unknown
- 2013-08-05 LT LTEP13748243.6T patent/LT2882440T/lt unknown
- 2013-08-05 ES ES13748243T patent/ES2717911T3/es active Active
- 2013-08-05 PL PL13748243T patent/PL2882440T3/pl unknown
- 2013-08-05 SI SI201331387T patent/SI2882440T1/sl unknown
- 2013-08-05 EA EA201590332A patent/EA028420B1/ru not_active IP Right Cessation
- 2013-08-05 RS RS20190351A patent/RS58734B1/sr unknown
- 2013-08-05 TR TR2019/04980T patent/TR201904980T4/tr unknown
- 2013-08-05 EP EP19159506.5A patent/EP3574904B1/en active Active
- 2013-08-05 KR KR1020157002982A patent/KR102112885B1/ko active Active
- 2013-08-06 JO JOP/2013/0236A patent/JOP20130236B1/ar active
- 2013-08-06 TW TW102128165A patent/TWI607754B/zh active
-
2015
- 2015-01-19 TN TNP2015000027A patent/TN2015000027A1/fr unknown
- 2015-01-26 IL IL236934A patent/IL236934B/en active IP Right Grant
- 2015-02-04 MA MA37829A patent/MA37829A1/fr unknown
- 2015-02-04 PH PH12015500246A patent/PH12015500246B1/en unknown
- 2015-02-06 GT GT201500025A patent/GT201500025A/es unknown
- 2015-02-06 CO CO15024921A patent/CO7200273A2/es unknown
- 2015-02-06 CL CL2015000294A patent/CL2015000294A1/es unknown
- 2015-03-06 EC ECIEPI20158695A patent/ECSP15008695A/es unknown
-
2018
- 2018-02-09 JP JP2018022248A patent/JP6595024B2/ja active Active
-
2019
- 2019-04-30 CY CY20191100461T patent/CY1122143T1/el unknown
- 2019-09-25 JP JP2019174353A patent/JP6974669B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015524472A5 (https=) | ||
| JP2014528464A5 (https=) | ||
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP2009526072A5 (https=) | ||
| JP2014511891A5 (https=) | ||
| JP2014139226A5 (https=) | ||
| JP2018109022A5 (https=) | ||
| JP2014511892A5 (https=) | ||
| JP2016506962A5 (https=) | ||
| JP2017519781A5 (https=) | ||
| JP2017502940A5 (https=) | ||
| JP2013527202A5 (https=) | ||
| CY1119227T1 (el) | Παραγωγα πυριδινης ως ηπιοι αναστολεις της rock | |
| JP2018512391A5 (https=) | ||
| JP2016505512A5 (https=) | ||
| JP2016506960A5 (https=) | ||
| JP2010529118A5 (https=) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| RU2017118165A (ru) | Ингибиторы энхансера гомолога 2 zestes | |
| JP2017504635A5 (https=) | ||
| JP2013523814A5 (https=) | ||
| JP2014525454A5 (https=) | ||
| JP2017505293A5 (https=) | ||
| JP2016540811A5 (https=) | ||
| RU2017145928A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) |